Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma

Michael B. Livingston, Megan H. Jagosky, Myra M. Robinson, William A. Ahrens, Jennifer H. Benbow, Carol J. Farhangfar, David M. Foureau, Deirdre M. Maxwell, Emily A. Baldrige, Xhevahire Begic, James T. Symanowski, Nury M. Steuerwald, Colin J. Anderson, Joshua C. Patt, Jeffrey S. Kneisl, Edward S. Kim

Clin Cancer Res (2021) 27 (23): 6424–6431.

https://doi.org/10.1158/1078-0432.CCR-21-2001

Published: 01 December 2021

View article titled, Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma

Includes: Supplementary data

Journal Articles

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Edward S. Kim, Thomas S. Uldrick, Caroline Schenkel, Suanna S. Bruinooge, R. Donald Harvey, Allison Magnuson, Alexander Spira, James L. Wade, Mark D. Stewart, Diana Merino Vega, Julia A. Beaver, Andrea M. Denicoff, Gwynn Ison, S. Percy Ivy, Suzanne George, Raymond P. Perez, Patricia A. Spears, William D. Tap, Richard L. Schilsky

Clin Cancer Res (2021) 27 (9): 2394–2399.

https://doi.org/10.1158/1078-0432.CCR-20-3852

Published: 01 May 2021

View article titled, Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Journal Articles

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett-Mayer, Whitney Rhodes, Edward Stepanski, Thomas S. Uldrick, Gwynn Ison, Sean Khozin, Wendy S. Rubinstein, Caroline Schenkel, Robert S. Miller, George A. Komatsoulis, Richard L. Schilsky, Edward S. Kim

Clin Cancer Res (2021) 27 (9): 2430–2434.

https://doi.org/10.1158/1078-0432.CCR-20-3857

Published: 01 May 2021

View article titled, Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-<em>Friends</em> Recommendations

Includes: Supplementary data

Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, Madison M. Wempe, Richard L. Schilsky, Edward S. Kim, James L. Wade, III

Clin Cancer Res (2021) 27 (9): 2408–2415.

https://doi.org/10.1158/1078-0432.CCR-20-3854

Published: 01 May 2021

View article titled, Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Journal Articles

Detection of NRG1 Gene Fusions in Solid Tumors

Sushma Jonna, Rebecca A. Feldman, Jeffrey Swensen, Zoran Gatalica, Wolfgang M. Korn, Hossein Borghaei, Patrick C. Ma, Jorge J. Nieva, Alexander I. Spira, Ari M. Vanderwalde, Antoinette J. Wozniak, Edward S. Kim, Stephen V. Liu

Clin Cancer Res (2019) 25 (16): 4966–4972.

https://doi.org/10.1158/1078-0432.CCR-19-0160

Published: 15 August 2019

View article titled, Detection of NRG1 Gene Fusions in Solid Tumors

Includes: Supplementary data

Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, Karen Kelly, Luis G. Paz-Ares, Pilar Garrido, Shadia Jalal, Daruka Mahadevan, Martin Gutierrez, Mariano Provencio, Eric Schaefer, Monte Shaheen, Erica L. Johnston, P. Kellie Turner, Siva Rama Prasad Kambhampati, Richard Beckmann, Anwar Hossain, William J. John, Jonathan W. Goldman

Clin Cancer Res (2018) 24 (22): 5543–5551.

https://doi.org/10.1158/1078-0432.CCR-18-0651

Published: 15 November 2018

View article titled, Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Includes: Supplementary data

Journal Articles

Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Kathryn F. Mileham, Edward S. Kim

Clin Cancer Res (2016) 22 (22): 5397–5399.

https://doi.org/10.1158/1078-0432.CCR-16-1710

Published: 14 November 2016

View article titled, Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Journal Articles

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew W. Stephens, Ronit Simantov, Srinivasu Poondru, Rich Gedrich, Scott M. Lippman, Stan B. Kaye, Craig P. Carden

Clin Cancer Res (2015) 21 (4): 693–700.

https://doi.org/10.1158/1078-0432.CCR-14-0265

Published: 16 February 2015

View article titled, Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy

Kathryn A. Gold, Edward S. Kim, Diane D. Liu, Ping Yuan, Carmen Behrens, Luisa M. Solis, Humam Kadara, David C. Rice, Ignacio I. Wistuba, Stephen G. Swisher, Wayne L. Hofstetter, J. Jack Lee, Waun K. Hong

Clin Cancer Res (2014) 20 (7): 1946–1954.

https://doi.org/10.1158/1078-0432.CCR-13-1959

Published: 31 March 2014

View article titled, Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy

Includes: Supplementary data

Journal Articles

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch, Ximing Tang, Garry Beran, Sonia Eckersley, Xin Wang, Rebecca P.A. Ellston, Simon Dearden, Sabina Cosulich, Paul D. Smith, Carmen Behrens, Edward S. Kim, Xinying Su, Shuqiong Fan, Neil Gray, David P. Blowers, Ignacio I. Wistuba, Chris Womack

Clin Cancer Res (2014) 20 (3): 595–603.

https://doi.org/10.1158/1078-0432.CCR-13-1638

Published: 02 February 2014

View article titled, Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Clin Cancer Res (2013) 19 (24): 6967–6975.

https://doi.org/10.1158/1078-0432.CCR-12-1818

Published: 16 December 2013

View article titled, Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Includes: Supplementary data

Journal Articles

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Robyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gutin, Jerry S. Lanchbury, Massimo Barberis, Edward S. Kim

Clin Cancer Res (2013) 19 (22): 6261–6271.

https://doi.org/10.1158/1078-0432.CCR-13-0596

Published: 14 November 2013

View article titled, Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

Includes: Supplementary data

Journal Articles

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Clin Cancer Res (2013) 19 (1): 279–290.

https://doi.org/10.1158/1078-0432.CCR-12-1558

Published: 02 January 2013

View article titled, An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Includes: Supplementary data

Journal Articles

New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Kathryn A. Gold, Ignacio I. Wistuba, Edward S. Kim

Clin Cancer Res (2012) 18 (11): 3002–3007.

https://doi.org/10.1158/1078-0432.CCR-11-2055

Published: 31 May 2012

View article titled, New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Journal Articles

ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia

Pierre Saintigny, Adel K. El-Naggar, Vali Papadimitrakopoulou, Hening Ren, You-Hong Fan, Lei Feng, J. Jack Lee, Edward S. Kim, Waun Ki Hong, Scott M. Lippman, Li Mao

Clin Cancer Res (2009) 15 (19): 6284–6291.

https://doi.org/10.1158/1078-0432.CCR-09-0498

Published: 30 September 2009

View article titled, ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia

Journal Articles

Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Seung Hyun Oh, Quanri Jin, Edward S. Kim, Fadlo R. Khuri, Ho-Young Lee

Clin Cancer Res (2008) 14 (5): 1581–1589.

https://doi.org/10.1158/1078-0432.CCR-07-0952

Published: 03 March 2008

View article titled, Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Journal Articles

Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

Floriana Morgillo, Woo-Young Kim, Edward S. Kim, Fortunato Ciardiello, Waun Ki Hong, Ho-Young Lee

Clin Cancer Res (2007) 13 (9): 2795–2803.

https://doi.org/10.1158/1078-0432.CCR-06-2077

Published: 01 May 2007

View article titled, Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Clin Cancer Res (2004) 10 (9): 2968–2976.

https://doi.org/10.1158/1078-0432.CCR-03-0412

Published: 06 May 2004

View article titled, Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

NARROW

Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Detection of NRG1 Gene Fusions in Solid Tumors

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia

Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only